New therapy options for patients with eosinophilic type of severe bronchial asthma
https://doi.org/10.21518/2079-701X-2019-21-111-116
Abstract
The article provides data on the epidemiology of severe asthma. It defines the phenotype and endotype of bronchial asthma and classifies BA according to phenotype/endotype. The features of the eosinophilic phenotype of severe bronchial asthma are considered. Clinical characteristics of the patient corresponding to the prescription of benralizumab are presented. The algorithm of decision making by a doctor-therapist about patients’ referral to a pulmonologist for consideration of the biological therapy issue is given. The results of the main clinical studies to assess the efficacy and safety of benralizumab in patients with severe eosinophilic bronchial asthma: SIROCCO, CALIMA, ZONDA, BORA are described. The experience of using various biological preparations for the treatment of severe asthma in Chelyabinsk and the Chelyabinsk Region has also been summarized.
About the Authors
G. L. Ignatova
South Ural State Medical University
Russian Federation
Russian Federation
Galina L. Ignatova, Dr. of Sci. (Med), Professor, Head of Therapy Department of the Institute for Additional Professional Education
64, Vorovsky street, Chelyabinsk, 454092, Russia
V. N. Antonov
South Ural State Medical University
Russian Federation
Russian Federation
Vladimir N. Antonov, Cand. of Sci. (Med), Associate Professor of the Department of Therapy at the Institute of Additional Professional Education
64, Vorovsky street, Chelyabinsk, 454092, Russia
E. V. Blinova
South Ural State Medical University
Russian Federation
Russian Federation
Elena V. Blinova, Cand. of Sci. (Med), Associate Professor of the Department of Therapy at the Institute of Additional Professional Education
64, Vorovsky street, Chelyabinsk, 454092, Russia
I. V. Grebneva
South Ural State Medical University
Russian Federation
Russian Federation
Irina V. Grebneva, Cand. of Sci. (Med), Department of Therapy at the Institute of Additional Professional Education
64, Vorovsky street, Chelyabinsk, 454092, Russia
E. V. Sheklanova
Chelyabinsk Regional Clinical Hospital No. 3
Russian Federation
Russian Federation
Elena V. Sheklanova, Cand. of Sci. (Med), Deputy Chief Physician for Treatment
287, avenue Pobeda, Chelyabinsk, 454021
References
1. Ненашева Н.М. Фенотипы бронхиальной астмы и выбор терапии. Практическая пульмонология. 2014;(2):2-11. Режим доступа: https://elibrary.ru/item.asp?id=23102918. Nenasheva N.M. Phenotypes of bronchial asthma and choice of therapy. Prakticheskaya pul’monologiya = Practical pulmonology. 2014;(2):2-11. (In Russ.) Available at: https://elibrary.ru/item.asp?id=23102918.
2. Tan L.D., Bratt J.M., Godor D., Louie S., Kenyon N.J. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;(9):71-81. doi: 10.2147/JAA.S78049.
3. Kolbeck R., Kozhich A., Koike M., Peng L., Andersson C.K., Damschroder M.M., Reed J.L., Woods R., Dall’acqua W.W., Stephens G.L. et al. MEDI-563,ahumanizedanti-IL-5receptoralphamAbwithenhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;(125):1344–1353. doi: 10.1016/j.jaci.2010.04.004.
4. Laviolette M., Gossage D.L., Gauvreau G., Leigh R., Olivenstein R., Katial R., Busse W.W., Wenzel S., Wu Y., Datta V. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;(132):1086–1096 e5. doi: 10.1016/j.jaci.2013.05.020.
5. Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P., Sproule S., Gilmartin G., Aurivillius M., Werkstrom V., et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;(388):2115–2127. doi: 10.1016/S0140-6736(16)31324-1.
6. FitzGerald J.M., Bleecker E.R., Nair P., Korn S., Ohta K., Lommatzsch M., Ferguson G.T., Busse W.W., Barker P., Sproule S., et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2016;(388):2128–2141. doi: 10.1016/S0140-6736(16)31322-8.
7. Goldman M., Hirsch I., Zangrilli J.G., Newbold P., Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: Subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;(33):1605–1613. doi: 10.1080/03007995.2017.1347091.
8. Nair P., Wenzel S., Rabe K.F., Bourdin A., Lugogo N.L., Kuna P., Barker P., Sproule S., Ponnarambil S., Goldman M., et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;(376):2448–2458. doi: 10.1056/NEJMoa1703501.
9. Busse W.W., Bleecker E.R., FitzGerald J.M., Ferguson G.T., Barker P., Sproule S., Olsson R.F., Martin U.J., Goldman M.; BORA Study Investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;(7):46–59. doi: 10.1016/S2213-2600(18)30406-5.
Review
For citations:
Ignatova GL, Antonov VN, Blinova EV, Grebneva IV, Sheklanova EV. New therapy options for patients with eosinophilic type of severe bronchial asthma. Meditsinskiy sovet = Medical Council. 2019;(21):111-116. (In Russ.) https://doi.org/10.21518/2079-701X-2019-21-111-116
Views:
680
Email this article 